Navigation Links
Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries

WALTHAM, Mass., Sept. 4, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details are undisclosed but include milestone payments and royalties on future entinostat sales. Details of the agreement include:

  • Eddingpharm receives exclusive rights to develop, market and sell entinostat in mainland China, Hong Kong, Thailand, Macau, Taiwan, Malaysia and Singapore
  • Eddingpharm receives rights to manufacture entinostat
  • Syndax will receive royalties on future entinostat sales
  • Eddingpharm may participate in entinostat's first three global Phase 3 registration trials
  • A joint development committee will oversee conduct of any trials
  • A joint commercialization committee will oversee marketing
  • Eddingpharm can explore further indications for entinostat in China
  • All data will be shared by both companies for regulatory purposes

"We look forward to working closely with Syndax to develop entinostat in breast and lung cancer as well as other indications," said Xin Ni, chairman and chief executive officer of Eddingpharm. "We are focused on bringing new and effective treatments to patients in our Asian communities and we believe this partnership with Syndax has the potential to help a large number of cancer patients across our Asian markets."

Arlene M. Morris, Syndax's chief executive officer added, "We view this agreement as the start of an important collaborative effort between our two companies. The agreement to a joint development committee, trial participation and sharing of data represents Eddingpharm's important commitment to that effort. The result will be a cooperative effort that has the potential to impact many patients in China suffering with advanced, treatment-resistant cancers."

About Entinostat

Entinostat, Syndax's lead product candidate, has been studied in more than 800 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies. Entinostat's established safety and efficacy profile as both a single agent and in combination with a number of commercially available targeted therapies differentiates it from other histone deacetylase inhibitors(HDACi). Having demonstrated promising clinical results in breast and lung cancer, entinostat is moving toward pivotal clinical testing. It is an oral, novel inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. This aberrant gene expression can result in reversible, epigenetically-based drug tolerance. Designed to selectively target the HDAC isoforms most relevant to the biology of tumors, entinostat can normalize dysregulated gene expression in cancer cells, thereby restoring sensitivity to targeted therapy. Entinostat is the first HDACi with positive results in a randomized Phase 2 study in breast cancer and is the only HDACi in late-stage development for this indication.

About Eddingpharm

Founded in 2001, Eddingpharm is a leading specialty pharmaceutical company in the fast growing China market, committed to actively introducing quality products into China's pharmaceutical market. The Company focuses on the development and promotion of pharmaceutical products in four therapeutic areas: medical nutrition, oncology, anti-infective and respiratory.  Eddingpharm has established long-term cooperative relationships with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. Eddingpharm recently established its US affiliate and set up a product development team with R&D capabilities in Los Angeles, CA, USA, to coordinate and communicate with leading global R&D institutions and explore opportunities for introducing innovative pharmaceutical products in China. The Company currently employs over 700 people.

More information can be found on

About Syndax Pharmaceuticals

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer. Entinostat also demonstrated promising results in a subset of non-small cell lung cancer patients when given in combination with the EGFR-TKI erlotinib (ENCORE 401). NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement aimed at improving survival in advanced, hard-to-treat cancers.

For more information, visit

Corporate Contact: 
Bob Goodenow 
Chief Business Officer 
Syndax Pharmaceuticals 
(781) 419-1418

Media Contacts: 
David Schull or Matt Middleman, M.D. 
Russo Partners 
(212) 845-4271 
(212) 845-4272

SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
4. Ruggles Family Foundation and Mr. and Mrs. Rudy L. Ruggles, Jr. Make $1.25M Donation to J. Craig Venter Institute for New Study to Identify and Elucidate Healthy Aging Biomarkers
5. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
6. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
7. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
8. Athens Regional Medical Center Boosts Patient Safety with Expanded Use of Capnography
9. CVS Caremark Hosts Grand Opening of State-of-the-Art Mail Service Pharmacy and Customer Center
10. INTERPHEX and Parenteral Drug Association Announce Agreement
11. Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)
Post Your Comments:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):